Poliomyelitis

Elizabeth Top Vander; Martha Gentry-Nielsen; Floyd C. Knoop

doi:10.1016/B978-008055232-3.60926-2

Poliomyelitis

Elizabeth Top Vander, Martha Gentry-Nielsen, Floyd C. Knoop

Department of Medical Microbiology and Immunology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Poliovirus caused several major epidemics in the early 1950's that resulted in about 21,000 cases per year in the United States. In 1955, an inactivated polio vaccine was developed that limited the spread of this feared disease. The Salk vaccine, combined with a live virus vaccine produced by Sabin, plus a comprehensive eradication campaign, have eliminated wild type poliomyelitis in the United States. However, there remain many patients who suffer from the sequelae of this disease through permanent paralysis and post-polio syndrome.

Original language	English (US)
Title of host publication	xPharm
Subtitle of host publication	The Comprehensive Pharmacology Reference
Publisher	Elsevier Inc.
Pages	1-4
Number of pages	4
ISBN (Print)	9780080552323
DOIs	https://doi.org/10.1016/B978-008055232-3.60926-2
State	Published - Dec 1 2011

All Science Journal Classification (ASJC) codes

Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1016/B978-008055232-3.60926-2

Cite this

@inbook{64b9a6eafd3742e5965b4c4920bc1809,

title = "Poliomyelitis",

abstract = "Poliovirus caused several major epidemics in the early 1950's that resulted in about 21,000 cases per year in the United States. In 1955, an inactivated polio vaccine was developed that limited the spread of this feared disease. The Salk vaccine, combined with a live virus vaccine produced by Sabin, plus a comprehensive eradication campaign, have eliminated wild type poliomyelitis in the United States. However, there remain many patients who suffer from the sequelae of this disease through permanent paralysis and post-polio syndrome.",

author = "Vander, {Elizabeth Top} and Martha Gentry-Nielsen and Knoop, {Floyd C.}",

year = "2011",

month = dec,

day = "1",

doi = "10.1016/B978-008055232-3.60926-2",

language = "English (US)",

isbn = "9780080552323",

pages = "1--4",

booktitle = "xPharm",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - Poliomyelitis

AU - Vander, Elizabeth Top

AU - Gentry-Nielsen, Martha

AU - Knoop, Floyd C.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Poliovirus caused several major epidemics in the early 1950's that resulted in about 21,000 cases per year in the United States. In 1955, an inactivated polio vaccine was developed that limited the spread of this feared disease. The Salk vaccine, combined with a live virus vaccine produced by Sabin, plus a comprehensive eradication campaign, have eliminated wild type poliomyelitis in the United States. However, there remain many patients who suffer from the sequelae of this disease through permanent paralysis and post-polio syndrome.

AB - Poliovirus caused several major epidemics in the early 1950's that resulted in about 21,000 cases per year in the United States. In 1955, an inactivated polio vaccine was developed that limited the spread of this feared disease. The Salk vaccine, combined with a live virus vaccine produced by Sabin, plus a comprehensive eradication campaign, have eliminated wild type poliomyelitis in the United States. However, there remain many patients who suffer from the sequelae of this disease through permanent paralysis and post-polio syndrome.

UR - http://www.scopus.com/inward/record.url?scp=84883900388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883900388&partnerID=8YFLogxK

U2 - 10.1016/B978-008055232-3.60926-2

DO - 10.1016/B978-008055232-3.60926-2

M3 - Chapter

AN - SCOPUS:84883900388

SN - 9780080552323

SP - 1

EP - 4

BT - xPharm

PB - Elsevier Inc.

ER -

Poliomyelitis

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this